Sifuvirtide (SFT) is a HIV peptide fusion inhibitor under Phase II clinical trials.
INTRODUCTION
The trimeric envelope gp120/gp41 complex of HIV-1 mediates viral entry by binding to cellular receptor CD4 and a co-receptor (CCR5 or CXCR4) and subsequently fusing the viral and cellular membranes(1,2). In the current fusion model, the receptor binding induces a series of coordinated structural changes in gp120 that trigger gp41 to expose, extend and insert its N-terminal hydrophobic fusion peptide into cell membranes(1-3).
The extended pre-hairpin intermediate conformation persists for at least 15 min and then collapses into a trimer-of-hairpins structure (six-helical bundle, 6-HB) that pulls the viral and cellular membranes into close contact for fusion (3) (4) (5) (6) . In this fusion-active gp41 core structure, three N-terminal heptad repeat region (NHR) form a central trimeric coiled coil, whereas three C-terminal heptad repeat region (CHR) around the NHR pack as antiparallel helices into hydrophobic grooves (3) (4) (5) (6) . A number of synthetic peptides derived from the NHR and CHR of gp41 can efficiently inhibit HIV-1 infection by competitively binding to the exposed NHR or CHR in the gp41 pre-hairpin state and hence blocking 6-HB formation in a dominant-negative manner (7) (8) (9) (10) (11) (12) (13) (14) (15) . Among them, T20 (Enfuvirtide, Fuzeon) has been approved for clinical use as the first member of a new class of anti-HIV drugs-HIV fusion inhibitors (9, 16, 17) . This peptide drug can suppress replication of HIV variants with multi-drug resistance to reverse transcriptase and protease inhibitors, however, it also easily induce resistance in both clinical settings and laboratory studies (17) (18) (19) (20) (21) .
Due to the drug-resistance problem, many efforts have been made to develop novel anti-HIV agents, including fusion inhibitors with improved stability and potency. In succession to T20, the second-generation peptide fusion inhibitor T1249 was developed with increased antiviral potency, but its clinical development was halted due to the drug formulation problem (14, 22, 23) . Among a series of more potent third-generation fusion inhibitors (10, (12) (13) (14) (15) , Sifuvirtide (SFT) is one in advance stage. It has been evaluated by the Phase I clinical trials and is currently under Phase II clinical studies (13, 24) . This peptide inhibitor was originally designed with different sequence and/or location in relationship to CHR peptides C34, T20 and T1249 on the basis of three-dimensional structural information of gp41 (13) . Our previous studies demonstrated its potent anti-HIV activity, good safety and pharmacokinetic profiles (13, 25) . In this study, we have performed a leading study to evaluate its antiviral spectrum by using two large panels of HIV-1 Env-pseudotyped viruses, corresponding to the subtypes A, B and C that dominate the AIDS epidemics worldwide, and the subtypes B', CRF07_BC (B/C) and CRF01_AE (A/E) recombinants that are the major circulating viruses in China. We have also tested the susceptibility of HIV-1 variants that possess cross-resistance the first and second generation fusion inhibitors (T20 and T1249). To elucidate its mechanism of action, we have solved the crystal structure of SFT in complex with its target NHR sequence by using the peptide N36 as a surrogate. The present results show very strong inhibition of SFT on diverse HIV-1 strains and reveal its key molecular determinants. These data have provided important information for developing SFT for clinical use and for designing novel HIV-1 fusion inhibitors.
EXPERIMENTAL PROCEDURES
Peptides synthesis -Peptides SFT (Acetyl-SWETWEREIENYTRQIYRIL EESQEQQDRNERDLLE-NH 2 ), T20 (Acetyl-YTSLIHSLIEESQNQQEKNE QELLELDKWASLWNWF-NH 2 ) and N36 (Acetyl-SGIVQQQNNLLRAIEAQQHL  LQLTVWGIKQLQARIL-NH 2 ) were synthesized by a standard solid-phase FMOC method. All three peptides were acetylated at the N-terminus and amidated at the C-terminus. They were purified by reversed-phase high-performance liquid chromatography (HPLC) and verified for purity >95% and correct amino acid composition by mass spectrometry. Concentrations of the peptides were determined by UV absorbance and a theoretically calculated molar-extinction coefficient (280 nm) of 5500 M based on the number of tryptophan and tyrosine residues (all the peptides tested contain Trp and/or Tyr), respectively. Cell lines -TZM-bl cells were contributed by J.C. Kappes and X. Wu through the ARRRP, Division of AIDS, NIAID, NIH. This reporter cell line stably expresses high levels of CD4, CCR5, and CXCR4 and contains Tat-responsive reporter genes for firefly luciferase and β-galactosidase under the control of an HIV-1 long terminal repeat promoter (26) . 293T cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Both of these adherent cell lines were maintained in Dulbecco's modified Eagle's medium (D-MEM) growth medium (Gibco/Invitrogen) containing 10% heat-inactivated fetal bovine serum (FBS). Cells were harvested using trypsin/EDTA solution (Invitrogen). All cell lines were maintained at 37°C in humidified air containing 5% CO 2 .
HIV-1 Env-expressing plasmids -
Inhibition of HIV-1 single-cycle infection -HIV-1 pseudoviruses were generated as described previously (27, 28) . Briefly, 293T cells (5 x 10 6 cells in 15 ml of growth medium in a T-75 culture flask) were cotransfected with 10 μg of an Env-expressing plasmid and 20μg of a backbone plasmid pSG3
Δenv that encodes Env-defective, luciferase-expressing HIV-1 genome using Lipofectamine 2000 reagent (Invitrogen).
Pseudovirus-containing culture supernatants were harvested 48 hours after transfection and filtered by 0.45-μm pore size, and stored at -80°C in 1-ml aliquots until use. The 50% tissue culture infectious dose (TCID 50 ) of a single thawed aliquot of each pseudovirus batch was determined in TZM-bl cells. The antiviral activity of SFT or T20 was determined using TZM-b1 cells as described previously. Briefly, the peptides were prepared with ten series dilutions in a 3-fold stepwise manner and mixed with 100 TCID 50 viruses and incubated 1 hour at room temperature. The mixture was added to 5 TZM-bl cells (10 4 /well) and incubation at 37°C for 48 hours. Luciferase activity was measured using luciferase assay regents (Promega, Medison, WI) and a Luminescence Counter (Promega) according to the manufacture's instructions. The percent inhibition by the peptides and 50% inhibitory concentration (IC 50 ) values were calculated as previously described (27, 28) .
Inhibition of HIV-1 NL4-3 variants-
HIV-1 molecular clone NL4-3 carrying L33S or L33V mutation was kindly provided by Dr. Frank Kirchhoff from the Institute of Virology, the University of Ulm, Ulm, Germany (29, 30) . The mutant viruses were generated by transient transfection of NL4-3 plasmids into 293T cells. The virus stocks were harvested 48 hours posttransfection and quantified for TCID 50 . Inhibition of the peptides (SFT and T20) on the NL4-3 mutants was performed as described for pseudoviruses. In brief, 100 TCID 50 viruses were used to infect TZM-bl cells in the absence or presence of serially diluted peptides. Two days post-infection, the cells were harvested and lysed in reporter lysis buffer, and the luciferase activity was measured. The IC 50 was calculated as described above using GraphPad Prism software (GraphPad Prism software Inc., San Diego, CA) .
Crystallization of SFT/N36 complex and structure determination -Equal amount of synthetic peptides SFT and N36 were dissolved in denaturing buffer (100 mM NaH 2 PO 4 , 10 mM Tris HCl pH 8.0, 8 M urea). To refold the peptides, the mixture was dialyzed against buffer containing 50 mM Tris-HCl pH7.5, 100 mM NaCl at 4℃ overnight. The dialyzed sample was clarified by centrifugation and subsequently loaded on size-exclusion column (Superdex75 10/300 GL, GE healthcare). Elutions corresponding to the molecular weight of a 6-HB were pooled and concentrated prior the crystallization trials. SFT/N36 complex was crystallized by mixing equal volume (0.8 μl) of purified protein (~10mg/ml) and reservoir solution (0.1 M Tris HCl pH 8.5 ， 10% w/v PEG4000) in a hanging drop vapor diffusion system at 22 o C. The cryocooling for the crystals was achieved by soaking the crystal 30-60 seconds in reservoir solution containing 30% glycerol (v/v) followed by flash freezing in liquid nitrogen. Complete data were collected at beamline PX III SLS (Villigen, Switzerland) using X ray with wavelength of 1.000Ǻ. The Crystal belonged to the space group of C2, contained a complete 6-HB (3 SFT and 3 N36 peptides) per asymmetric unit (ASU), diffracted the X ray to the resolution limit of 1.7 Ǻ. The structure of SFT/N36 was solved by molecular replacement (Phaser, CCP4 suite) using a truncated HIV-1 gp41 core structure (PDB ID: 1ENV) as searching model. The resolution range of the data used in molecular replacement was 44.390-3.0Ǻ. Phaser reported a single solution with final LLG (log-likelihood gain) value of 2479 and TFZ (the translation function Z-score) value of 25.9, indicating a correct solution. The R-factor of the initial solution was 43.39. The molecular replacement resulted in an interpretable electron density map. The initial electron density map was improved by manual model building (Coot v0.6). The structures were refined using PHENIX (31) . The final atomic models have good refinement statistics and stereochemistry qualities (Table 3 ). The structure is validated by MolProbity analysis (32) . The MolProbity score is 1.89, rating 72 rd percentile among structures of comparable resolution. The Ramachandran plot finds 99.52% residues in the favored area and 0.48% outliers. Hydrogen bond or salt bridge is defined according to measurements in the final atomic model. To define a hydrogen bond: the distance from donor hydrogen to the electronegative acceptor is ≤ 3.0Ǻ and the angle "donor-H-acceptor" is ≥ 120 o . To define a salt bridge, the distance between the positively charged atom of basic residue (K or R) and negatively charged atom on acidic residues (E or D) is ≤4 Ǻ.
RESULTS

Potent inhibition of SFT on diverse
HIV-1 subtypes and variants-One of the obstacles to treatment of the HIV-1 is its extremely high genetic variability, which results in three major groups with many subtypes and circulating recombinant forms (CRFs) (33, 34) . Although SFT has been advanced into clinical trials, only limited HIV-1 subtypes and variants have been tested for the susceptibility. Here, we firstly evaluated SFT with a panel of 14 HIV-1 pseudoviruses derived from subtypes A, B and C that represent the vast majority of HIV-1 infections worldwide. As shown in Table 1 (17) (18) (19) (20) (21) . Our previous studies demonstrated that SFT possessed efficient potency to inhibit HIV-1 variants that carry single or double T20-resistant mutations (e.g. V38A, V38A/N42T, N42T/N43K) (13) . Here, we investigated whether L33S mutation affects SFT sensitivity, because recent data showed that this point mutation confers cross-resistance to both first generation fusion inhibitor T20 and second generation fusion inhibitor T1249 (14, 29, 30) . Prominently, SFT could potently inhibit HIV-1 molecular clone NL4-3 carrying L33S mutation with an IC 50 of 0.41 nM, while T20 had no inhibitory activity at a concentration as high as 750 nM (Fig. 1A) . Further, we observed whether L33V mutation affects SFT sensitivity, because this naturally-occurring mutation in treatment-naïve patients has been shown to confer T20-resistance (29) . Similarly, SFT had an IC 50 value at 0.22 nM, while T20 had an IC 50 at 665.40 nM (Fig. 1B) . These data highlight that SFT has a potent and broad anti-HIV activity, not only for currently circulating subtypes but also for inhibitor-induced and naturally-occurring T20-resistant variants.
Crystallization and structure determination of SFT/N36 complexIn order to elucidate the structural basis of the potent efficacy of SFT, we assembled and crystallized SFT/N36 complex. We dissolved equal amount of synthetic N36 and SFT peptides in denaturing buffer. The mixture was dialyzed to allow refolding of the peptides. The 6-HB formed by SFT/N36 peptides was purified by size-exclusion chromatography.
The crystal of SFT/N36 complex belonged to the space group of C2, contained three pairs of SFT/N36 peptides (one complete 6-HB) per ASU, and diffracted X ray to a resolution limit of 1.70Ǻ. We could build all residues of SFT/N36 peptides including the N-terminal protection groups of the synthetic peptides in the electron density. The refined model has good refinement statistics and stereochemistry qualities (Table 3 ).
Structure of 6-HB with SFT/N36-We previously designed SFT based on the structural data of HIV gp41 core domain and computer modeling. We found that SFT could form highly thermostable 6-HB with its NHR counterpart in solution (13) .
As anticipated, the crystal structure of SFT/N36 complex resembles a typical 6-HB similar to other HIV gp41 core structures (Fig.S1 , Fig.2A) (4-6,37) . SFT adopts fully helical conformation when complexed with N36 ( Fig. 2A) . SFT is comprised of 36 amino acids, which is different from its parental sequence in 9 residues and is different from C34 in 16 residues. In the rational design of SFT, we engineered multiple pairs of basic and acidic residues (glutamic acid and arginine) to promote the ion pair formation between i and i+4 positions on SFT. We could observe all predicted salt bridges in our crystal structure (Fig. 2A) . Due to these residues are surface-exposed, many of them adopt alternative conformations. For example, Arg133 adopts two conformations, in which conformation A (35% occupancies) forms a salt bridge with Glu137 and conformation B (65% occupancies) forms another salt bridge with Glu136. Arg144 adopts two conformations, in which conformation A (69% occupancies) forms a salt bridge with Glu140 and conformation B (31% occupancies) forms another salt bridge with Glu148 ( Fig. 2A) . Thus, the salt bridges observed on SFT helix involve not only the residues at i and i+4 positions, but also other charged residues, which together stabilize the α-helical conformation of the peptide.
To stabilize the pocket binding domain, we replaced the Glu119 of the parental sequence by an uncharged residue threonine in the inhibitor design. The crystal structure shows that the side chain of Thr119 is positioned above the pocket binding domain (Fig. 3A) , functioning to stabilize the hydrophobic pocket. We previously introduced a serine residue to the N-terminus of SFT to improve the stability of the peptide. As illustrated in Fig. 3A , the acetyl-serine caps the N-terminus of SFT, hence the residue is denoted as capping serine. The carbonyl group of the capping serine accepts a hydrogen bond from NH group of Trp120 and its acetyl group accepts another hydrogen bond from NH group of Thr119. Therefore, the capping serine can stabilize of α-helical conformation of SFT.
As the results of SFT design, novel salt bridges and hydrogen bond were found between SFT and N36 peptides. As shown in Fig. 3B , the side chain of Glu137 on SFT forms a salt bridge with the side chain of Arg46 on N36-b. Comparing with HIV gp41 core structure containing C34 sequence (PDB ID:1ENV), residue Asp121 is replaced by Glu121 in SFT. Our structure indicates that the longer glutamic acid side chain of Glu121 could reach closer to the side chain of Lys63 on N36-a, resulting a stronger salt bridge. Residue His132 of C34 is substituted by Tyr132 in SFT, resulting a hydrogen bond between Oη atom of the tyrosine and Nε2 atom of Gln56 on N36-a (2.33Ǻ, 129 o ). In summary, the crystal structure of SFT/N36 complex confirms that the designing of the inhibitor could provide the following advantages. The mutations at N-terminal of SFT stabilize the conformation of this portion. The introduction of the charged residues promotes salt bridges formation that favors the helical conformation of the SFT as well as the inter-helical interactions between the inhibitor and the targeting sequence on NHR.
Structural basis for HIV-1 resistance to SFT -We have recently identified SFT-resistant HIV-1 variants and characterized several novel substitutions on NHR region of gp41, which are critical in conferring the resistant phenotypes (24) . For example, HIV-1 variant with N43K substitution is resistant to both SFT and T20. The mutation can lead to the reduced 6-HB stability and virus infectivity. The structure of SFT/N36 complex demonstrates that residue Asn43 is deeply buried inside the 6-HB, where the electron densities are well defined. The residue involves a cluster of highly conserved residues forming an extensive hydrogen bond network that mediate the interactions between N36 and SFT helices (Fig. 4A) . The side chain of Asn43 accepts a hydrogen bond from Arg46 and donates a hydrogen bond to Gln40 on N36 peptide, stabilizing the helical conformation of N36. The side chains of Asn43 and Gln141 coordinate an ordered water molecule; Gln40 donate a hydrogen bond to Gln142 on SFT, stabilizing the interaction between SFT and N36 helices. Thus, the functionality of an asparagine side chain of Asn43 is fully required for maintaining of the hydrogen network. Substitution of this residue could lead to the disruption of the network, causing the destabilization of the α-helical conformation of NHR and SFT/NHR interactions.
Residue Gln41 belongs to the remarkable glutamine-rich (Q-rich) polar layer that is critical for the overall stability of the 6-HB structure (4-6). A network of hydrogen bonds connect the residues within the Q-rich layer (Fig.  3B) , in which three Gln41 interacts with each other and simultaneously coordinate three water molecules together with Gln142 and Asn145 on three SFT. Interestingly, three Gln41 side chains are not symmetric in threefold; two Gln41 side chains adopt alternative conformations, reflecting a certain level of flexibility of this hydrogen network. The structure indicates that the functionality of glutamine side chain of Gln41 is irreplaceable for maintaining the overall structure of the Q-rich polar layer. Substitutions of Gln41 may result in the disruption of the layer, leading to not only the destabilization of trimeric NHR coiled coil but also the interactions between SFT/NHR helices. Evidenced by our previous studies(24), HIV-1 variants carrying Q41K, Q41H or Q41R mutations are highly resistant to SFT and T20. Substitutions of Gln41 could lead to the destabilization of 6-HB and reduced virus infectivity.
Residues Ile37 and Val38 are members of a non-polar layer of the 6-HB formed by SFT/N36 helices. There are sufficient electron densities defining the conformations of all residues in the non-polar layer (Fig. 4C) . Three Ile37 are located around the threefold symmetry axis of the trimeric N36 coiled coil with their side chains facing each other. Three Val38 side chains face the hydrophobic region comprised of Leu149, Glu146 and Asn145 on SFT. The structure indicates that the hydrophobic interactions among residues in this layer are important to the stability of NHR trimeric core and the interaction between SFT/NHR.
Substitutions of Ile37 and Val38 by polar residue, threonine or by less hydrophobic residues, alanine or methionine can destabilize the trimeric NHR coiled coil and the interaction between SFT/NHR.
DISCUSSION
T20 is the first and only HIV fusion inhibitor approved for salvage therapy of HIV/AIDS patients failed to current cocktails of inhibitors directed against viral enzymes (9, 16) . The fact of T20 can also induce drug-resistance has sparked the development of new generation peptide fusion inhibitors that not only preserve the potency against both wild-type and resistant-type viruses but also has improved pharmacokinetic profiles (17) (18) (19) (20) (21) . Based on this principle, SFT was engineered with several characteristics that facilitate its antiviral activity (13) . The charged glutamic acid and lysine residues were introduced into the solvent accessible site while the residues responsible for the NHR binding were maintained unchanged; Further, the residue Glu119 was replaced by threonine with an intention to stabilize the hydrophobic NHR pocket and a serine residue was added into the N-terminus of SFT to increase its stability (13) . Like T20, SFT is delivered by subcutaneous injection but has a dramatic prolonged decay half-life (13) . In this study, we have finely characterized its anti-HIV spectrum by using two large panels of Env-pseudotyped viruses in single-cycle infection assays and two HIV-1 variants that carry T20-resistant mutations, and determined its structural basis by crystallographic studies.
HIV-1 evolves with the great genetic diversity and can be classified into three major groups: M (major), O (outlier) and N (non-M non-O or new) (33, 34) . The M group viruses cause the vast majority of HIV-1 pandemic and can be further divided into many subtypes, including A-D, F-H, J and K, as well as several circulating and unique recombinant forms (CRFs and URFs). Some in vitro and in vivo observations suggest that the various subtypes may respond differently to certain antiretroviral drugs (38) (39) (40) (41) (42) (43) . The sequence diversity has raised concerns over the peptide fusion inhibitors that target the highly variable HIV-1 Envs. With the first panel of reference viruses, we showed that SFT could efficiently inhibit the subtypes A, B and C viruses that dominate the AIDS epidemics worldwide. Recently, the genetic diversity of HIV-1 subtypes has been found in China. According to the epidemiological data, the recombinant forms CRF07_BC and CRF01_AE, and subtype B' (Tai B) viruses are responsible for nationwide HIV-1 infections at 50.2%, 15.54% and 29.11% respectively (with a total of ~95%) (35, 36) . It is know that the Env genes of CRF01_BC originate from the subtype C viruses, but some studies indicate that this recombinant form of virus has unique biological characteristics (44) (45) (46) . For example, it is found that CRF01_BC strains exclusively use CCR5 co-receptor for infection and are highly resistant to the known broadly neutralizing antibodies (44, 45) . With the second large panel of HIV-1 pseudoviruses corresponding to the CRF07_BC, CRF01_AE, and B' subtypes, SFT consistently shows its potency to overcome the genetic diversity. It was noticed that several isolates (e.g. pRHPA4259 and GX2010.36H) were less sensitive to both SFT and T20, but sequence analyses of Envs had not identified the known mutations related to fusion inhibitor-resistance phenotypes (Supplemental Fig. S2 and Table S1 ).
Previous studies showed that SFT could sustain its inhibitory function on a panel of HIV-1 variants that carry T20-resistant genotypes in the peptide binding site of the gp41 NHR domain, typically including the 36 GIV 38 motif and its downstream residues (13) . The present studies further show that HIV-1 variants with L33S or L33V mutations are highly susceptible on SFT inhibition. The L33S mutant was initially induced by the peptide C34 and showed cross-resistance to T20 and T1249 (29, 47) . The L33V mutant was identified as a naturally-occurring mutation in treatment-naïve patients and showed T20-resistance (29) . Taken together, these data indicate that SFT has a high genetic barrier for drug-resistance.
Since the finding of T20, several crystallographic studies have been performed and revealed the core structure of HIV-1 gp41 that represents a post-fusion conformation(4-6,37,48). On the basis of gp41 core structure, a number of peptide fusion inhibitors have been designed to improve the antiviral and pharmacookinetic properties (14, 49) . However, there are limited structural data available for the engineered peptides. Recently, an electrostatically constrained α-helical peptide, SC34EK, was reported with the crystal structure (50) . It revealed that the interaction between SC34EK and N36 peptides was well preserved by contacts of hydrophobic interactive residues, and that the introduction of the charged EK motifs at the solvent accessible site of the peptide C34 could provide the salt-bridges that stabilize the α-helices and electrostatic interactions (50) . In this study, we provide the accurate structural insights into SFT/N36 complex. The crystal structure fully support the inhibitor design, offering the detailed molecular basis for the potent antiviral activity (13) . SFT is electrostatically constrained by seven salt bridges, conferring the outstanding thermostability. In order to stabilize the hydrophobic pocket, residue 119 is mutated to threonine in SFT, whereas the corresponding residue in C34 and T1249 is glutamic acid. Although none of the residues is hydrophobic, threonine is more hydrophobic than glutamic acid according to Wimley-White hydrophobicity scales (51) . Additionally, glutamic acid side chain is flexible comparing to the rigid, β-branched threonine side chain that is important to stabilize the hydrophobic interaction. The structure constraining C34 sequence (PDB ID 1ENV) shows that the side chain of Glu117 points away from the hydrophobic pocket where it could reach the solvent.
We previously identified that HIV-1 mutants with substitutions of Gln41, Asn43 or double substitutions Ile37/Val38 on gp41 displayed SFT resistance (24) . From our structural data, we can deduce the mechanisms for SFT resistance, which is consistent with four inhibitor resistant mechanisms (reduced contact, steric obstruction, electrostatic repulsion, and electrostatic attraction) proposed by Eggink et al (14) . More importantly, our data suggest the novel resistant mechanisms that are in many cases combined with T20 resistant mechanisms. Gln41 is located at the center of a Q-rich polar layer, the conserved structural features in HIV and SIV strains, which is crucial for 6-HB stability. Substitutions of Gln41 could disrupt the hydrogen bond network. Therefore, substitutions Q41K or Q41R can not only fit the "electrostatic repulsion" mechanism but also fit a novel mechanism of "hydrogen bond disruption". Similarly, Asn43 is part of a hydrogen bind network mediating the interaction between N-and C-helices. N43K mutation could disrupt the hydrogen network; therefore, the mutation can fit both "steric obstruction" and "hydrogen bond disruption" mechanisms. Ile37 and Val38 are part of a non-polar layer of 6-HB. Isoleucine and valine are the most hydrophobic residues(51) with rigid β-branched side chain, which is ideal for stable hydrophobic interactions. Substitutions I37T, V38A, V38M could lead to the destabilization of hydrophobic interactions; therefore, these mutations can fit the novel resistance mechanism of "hydrophobic contact disruption". It is worth noticing that residues Ile37, Val38, Asn41 and Gln43 are involve in the interactions with the unchanged residues in both SFT and T20, supporting the fact that HIV-1 with these mutations displayed cross-resistance against both inhibitors.
In conclusion, our present studies have demonstrated the potent anti-HIV activity of SFT and its structural basis. The data provide important information for developing SFT for clinical use and for designing novel HIV fusion inhibitors. The sequence alignment of SFT, its parental sequence (HIV-1 subtype E gp41 CHR 117-151 ) and C34. Numbering is based on the sequence of HXB2 gp41. The color codes for SFT sequence are: yellow, N-terminal capping acetyl-serine; green, mutation to stabilize the hydrophobic pocket; red, residues were changed to negatively charged residues; blue, residues were changed to positively charged residues; black, unchanged residues. Salt bridges observed in the crystal structure of SFT are indicated with the linkers. 
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